Posted on by Newsdesk

Lumexa Imaging Announces Third Quarter 2026 Results

RALEIGH, N.C., Nov. 10, 2026 (GLOBE NEWSWIRE) — Lumexa Imaging (Nasdaq: LMRI), one of the nation’s largest providers of outpatient imaging services, today reported results for the third quarter ended September 30, 2026.

“In Q3, we advanced our business in several meaningful ways while executing against our strategy. Advanced modalities reached a record high as a percent of our volumes, and our newer de novo cohorts continue to ramp on plan. We are actively opening three new de novo centers and are on pace to achieve our goal for 8–10 new center openings this year,” said Caitlin Zulla, Chief Executive Officer of Lumexa Imaging. “These achievements mark progress toward our long-term growth plans, and that progress is translating into strong, durable cash generation. We enter the fourth quarter confident in our ability to deliver for patients, partners, and shareholders.”

“We are leading a transformation in healthcare – delivering high-quality imaging in more convenient settings, more quickly and at meaningfully lower cost through our wholly owned centers and alongside health system partners, improving clinical and financial outcomes.”

Third Quarter 2026 Highlights

All comparisons are to the quarter ended September 30, 2025, unless otherwise noted

  • Revenue growth of 5.0% consolidated and 7.7% system-wide; consolidated revenues of $272.0 million as compared to $258.9 million
  • Advanced outpatient volume growth of 7.9% consolidated and 8.1% system-wide
  • Same-center advanced outpatient volume growth of 6.6% consolidated and 6.8% system-wide
  • Advanced procedure mix of 31.8% consolidated and 38.2% system-wide, up 127 and 145 basis points, respectively
  • Net income of $7.2 million as compared to net loss of $3.5 million
  • Adjusted EBITDA of $62.6 million as compared to $59.1 million; and a 23.0% Adjusted EBITDA margin as compared to 22.8%
  • GAAP EPS of $0.07 per share and Adjusted EPS of $0.26 per share

2026 Full Year Outlook:

Lumexa Imaging provided an update on its guidance for the full year ended December 31, 2026.

  • Reiterating full-year 2026 consolidated revenue guidance of $1.045 billion to $1.097 billion.
  • Narrowing its full-year 2026 Adjusted EBITDA guidance range to $236 million to $240 million, from its prior range of $235 million to $241 million. The midpoint of $238 million is unchanged. This includes approximately $7 million of public company costs that were not incurred in 2025. (At the midpoint of guidance, the addition of these costs lowers Adjusted EBITDA growth for 2026 versus 2025 from 7% to 4%)
  • Raising guidance for Adjusted EPS to $0.86 to $0.90 from $0.71 to $0.77 per share, driven by lower assumed effective tax rate.

Lumexa Imaging Earnings Conference Call and Webcast

Lumexa Imaging will host a conference call to discuss its third quarter 2026 results on November 10, 2026 at 5:00 p.m. ET. The call can be accessed via live audio webcast online at ir.lumexaimaging.com. A replay of the webcast will be available at the same link shortly after the completion of the call and will remain available for approximately one year.

Statement Regarding Use of Non-GAAP Financial Measures

This press release uses Adjusted EBITDA and Adjusted EPS, financial measures that are not calculated in accordance with GAAP. We use  Adjusted EBITDA and Adjusted EPS, in conjunction with GAAP financial measures, as an integral part of managing our business and to, among other things: (i) monitor and evaluate the performance of our business operations and financial performance; (ii) facilitate internal comparisons of the historical operating performance of our business operations; (iii) review and assess the operating performance of our management team; and (iv) analyze and evaluate financial and strategic planning decisions regarding future operations and annual operating budgets. For a reconciliation of Adjusted EBITDA and Adjusted EPS to the most directly comparable measure calculated in accordance with GAAP, please see below.

We have not reconciled our Adjusted EBITDA or Adjusted EPS guidance to their most directly comparable GAAP measures because we do not and are not able to provide guidance for those GAAP measures due to the uncertainty and potential variability of certain reconciling items, including transaction costs, severance and executive recruiting. Because such items cannot be provided without unreasonable efforts, we are unable to provide the corresponding reconciliations. However, such reconciling items could have a significant impact on our future results.

About Lumexa Imaging

Lumexa Imaging is a nationwide provider of outpatient medical imaging. With over 5,000 team members and approximately 190 outpatient imaging centers, our team conducted approximately 4 million outpatient procedures system-wide in 2025. We are a partner of choice for health systems and radiologists, delivering best-in-class clinical excellence, operations, and state-of-the-art technology across our platform.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this press release may be forward-looking statements. Forward-looking statements generally relate to future events or our future financial or operating performance. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” or “will,” or the negative of these words or other similar terms or expressions that concern our expectations, strategy, plans or intentions. Forward-looking statements in this release include, but are not limited to, statements regarding our expectations regarding our financial position and operating performance, including our guidance for full year 2026 and our assumptions underlying such guidance; and our ability to drive future growth and execute on our goals and strategies. Our expectations and beliefs regarding these matters may not materialize, and actual results in future periods are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including but not limited to those risk factors identified in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of our Annual Report on Form 10-K for the year ended December 31, 2025 and our later dated Quarterly Reports on Form 10-Q, each as filed with the Securities and Exchange Commission. The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligations to update any forward-looking statements, except as required by law.

Investor Contact

Sue Dooley
Lumexa Imaging
[email protected]

Media Contact

Melissa Weston
Lumexa Imaging
[email protected]



Lumexa Imaging Q3 2026 Outpatient Volumes Highlights:

Consolidated 3Q26   3Q25    Increase YoY
  Consolidated total procedures 631,131   609,352   3.6%
  Consolidated advanced procedures 200,600   185,913   7.9%
  % advanced procedures 31.8%   30.5%   127bps
  Consolidated same-center advanced volume growth ——   ——   6.6%
System-wide          
  System-wide total procedures 1,049,491   1,009,029   4.0%
  System-wide advanced procedures 400,581   370,501   8.1%
  % advanced procedures 38.2%   36.7%   145bps
  System-wide same-center advanced volume growth ——   ——   6.8%
Note: Advanced Procedures includes MRI and CT modalities. As of September 30, 2026 Center count was 190 total, 87 JV and 103 consolidated.
             

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(IN THOUSANDS, EXCEPT FOR COMMON SHARES)
(Unaudited)
    September 30, 2026   December 31, 2025
         
ASSETS        
Cash and cash equivalents   $ 90,011     $ 58,828  
Accounts receivable     117,769       112,942  
Accounts receivable, related party     22,570       18,893  
Other receivables     33,174       19,015  
Prepaid expenses     14,789       17,582  
Total current assets     278,313       227,260  
Property and equipment, net of accumulated depreciation     158,847       144,709  
Operating lease right-of-use assets     74,833       76,555  
Investments in unconsolidated affiliates     428,019       423,191  
Intangible assets, net of accumulated amortization     38,582       41,335  
Goodwill     807,554       807,554  
Other assets     46,988       43,953  
TOTAL ASSETS   $ 1,833,136     $ 1,764,557  
LIABILITIES AND EQUITY        
Accounts payable   $ 20,382     $ 44,857  
Accrued expenses and other current liabilities     117,920       95,561  
Accounts receivable pledging arrangement     2,322       1,599  
Current portion of long-term debt     15,548       13,112  
Current portion of finance lease liabilities     15,007       11,552  
Current portion of operating lease liabilities     12,277       12,513  
Total current liabilities     183,456       179,194  
Long-term debt, less current maturities     821,524       819,029  
Long-term finance lease liabilities, less current maturities     39,782       33,262  
Long-term operating lease liabilities, less current maturities     70,377       71,437  
Deferred income taxes     47,044       40,772  
Other liabilities     36,870       34,740  
Total liabilities     1,199,053       1,178,434  
COMMITMENTS AND CONTINGENCIES        
EQUITY:        
Common stock, $0.001 par value, 1,000,000,000 shares
authorized, 96,062,177 shares issued and outstanding at
September 30, 2026 and 96,109,927 shares issued and
outstanding at December 31, 2025		     96       96  
Additional paid-in-capital     1,253,407       1,217,087  
Accumulated deficit     (619,420 )     (631,060 )
Total equity     634,083       586,123  
TOTAL LIABILITIES AND EQUITY   $ 1,833,136     $ 1,764,557  

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE DATA)
(Unaudited)
         
    Three Months Ended September 30,
      2026     2025  
REVENUES:        
Net patient service revenue   $ 211,115   $ 201,695  
Management fee and other revenue     60,858     57,249  
Total revenues     271,973     258,944  
OPERATING EXPENSES:        
Cost of operations, excluding depreciation and amortization     225,571     219,236  
General and administrative expenses     30,025     17,081  
Depreciation and amortization     10,331     9,654  
Loss on disposal of property and equipment     779     623  
Total operating expenses     266,706     246,594  
Equity in earnings of unconsolidated affiliates     22,846     17,990  
INCOME FROM OPERATIONS     28,113     30,340  
OTHER EXPENSES:        
Interest expense     15,674     30,577  
Fair market value adjustment on debt     654     –  
Total other expenses     16,328     30,577  
INCOME (LOSS) BEFORE INCOME TAXES     11,785     (237 )
Income tax provision     4,607     3,264  
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)   $ 7,178   $ (3,501 )
         
Weighted average shares outstanding:        
Basic     95,983,246     69,531,530  
Diluted     96,256,077     69,531,530  
Net income (loss) per common share        
Basic   $ 0.07   $ (0.05 )
Diluted   $ 0.07   $ (0.05 )

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME (LOSS)
(IN THOUSANDS, EXCEPT FOR SHARE AND PER SHARE DATA)
(Unaudited)
         
    Nine Months Ended September 30,
      2026     2025  
REVENUES:        
Net patient service revenue   $ 612,168   $ 592,178  
Management fee and other revenue     176,504     163,169  
Total revenues     788,672     755,347  
OPERATING EXPENSES:        
Cost of operations, excluding depreciation and amortization     668,611     639,898  
General and administrative expenses     74,757     53,262  
Depreciation and amortization     30,336     27,984  
Loss on disposal of property and equipment     892     477  
Total operating expenses     774,596     721,621  
Equity in earnings of unconsolidated affiliates     56,489     49,835  
INCOME FROM OPERATIONS     70,565     83,561  
OTHER EXPENSES:        
Interest expense     48,227     90,523  
Loss on extinguishment and modification of debt     1,053     –  
Fair market value adjustment on debt     654     –  
Total other expenses     49,934     90,523  
INCOME (LOSS) BEFORE INCOME TAXES     20,631     (6,962 )
Income tax provision     8,991     11,452  
NET INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS)   $ 11,640   $ (18,414 )
         
Weighted average shares outstanding:        
Basic     95,983,242     69,527,181  
Diluted     96,092,916     69,527,181  
Net income (loss) per common share        
Basic   $ 0.12   $ (0.26 )
Diluted   $ 0.12   $ (0.26 )

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(IN THOUSANDS)
(Unaudited)
         
    Nine Months Ended September 30,
      2026       2025  
CASH FLOWS FROM OPERATING ACTIVITIES:        
Net income (loss)   $ 11,640     $ (18,414 )
Adjustments to reconcile net income (loss) to net cash provided by operating activities        
Depreciation and amortization     30,336       27,984  
Amortization of operating lease right-of-use assets     11,879       11,162  
Amortization of debt issuance costs     2,161       4,337  
Amortization of cloud computing implementation costs     1,332       271  
Unrealized fair market value adjustment on debt     263       –  
Write-off of debt issuance costs related to extinguishment of debt     46       –  
Equity in earnings of unconsolidated affiliates     (56,489 )     (49,835 )
Distributions from investments in unconsolidated affiliates     55,028       41,223  
Loss on disposal of property and equipment     892       477  
Deferred income taxes     6,272       3,502  
Stock-based compensation     37,350       23,032  
Other     (1,030 )     –  
Changes in operating assets and liabilities:        
Accounts receivable     (4,827 )     (7,206 )
Accounts receivable, related party     (3,677 )     2,189  
Capitalized cloud computing implementation costs     (2,773 )     (1,686 )
Other receivables     (14,159 )     (7,494 )
Prepaid expenses     2,094       (6,369 )
Other assets     (2,196 )     (15,418 )
Accounts payable     (24,475 )     5,007  
Accrued expenses and other current liabilities     29,725       (10,889 )
Other liabilities     2,605       7,700  
Operating lease liabilities     (11,453 )     (9,602 )
Net cash provided by (used in) operating activities     70,544       (29 )
CASH FLOWS FROM INVESTING ACTIVITIES:        
Proceeds from sale or disposal of property and equipment     196       794  
Acquisition of intangible asset     (600 )     –  
Purchases of property and equipment     (29,192 )     (19,228 )
Contributions to investments in unconsolidated affiliates     (3,366 )     (123 )
Net cash used in investing activities     (32,962 )     (18,557 )
CASH FLOWS FROM FINANCING ACTIVITIES:        
Payment of third-party debt issuance costs     (154 )     –  
Proceeds from long-term debt     15,675       2,818  
Payments of long-term debt     (11,925 )     (11,807 )
Proceeds from revolving line of credit     –       5,000  
Payments of finance lease liabilities     (10,455 )     (4,926 )
Capital contributions     –       835  
Proceeds from accounts receivable pledging arrangement     1,080       726  
Repayments on accounts receivable pledging arrangement     (620 )     –  
Net cash used in financing activities     (6,399 )     (7,354 )
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS     31,183       (25,940 )
CASH AND CASH EQUIVALENTS, beginning of period     58,828       26,131  
CASH AND CASH EQUIVALENTS, end of period   $ 90,011     $ 191  

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
(IN THOUSANDS)
(Unaudited)
         
    Three Months Ended September 30,
      2026       2025  
         
Net income (loss)   $ 7,178     $ (3,501 )
Depreciation and amortization     10,331       9,654  
Income tax provision     4,607       3,264  
Amortization of basis difference     573       500  
Interest expense     15,674       30,577  
Stock-based compensation     12,339       8,312  
Loss on disposal of property and equipment     779       623  
Fair market value adjustment on debt     654       –  
Severance and executive recruiting(1)     622       365  
Strategic initiatives and implementation(2)     2,365       1,198  
Transaction costs(3)     (661 )     2,899  
Litigation and settlements(4)     3,578       (14 )
Other(5)     362       728  
Adjustments for equity in earnings        
of unconsolidated affiliates(6)     4,194       4,525  
Adjusted EBITDA   $ 62,595     $ 59,130  
         
         
(1)Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
(2)Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives related to the deployment of a new technology system, the development, customization, and integration of a new enterprise resource planning system, and related transformation of our finance organization, including enhancements to our accounting capabilities and internal control processes.                    
(3)Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
(4)Consists of litigation and settlement costs for matters not related to core operations.
(5)Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.    
(6)To adjust for Lumexa Imaging’s proportional share of depreciation and amortization, interest expense and losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
RECONCILIATION OF GAAP NET INCOME (LOSS) TO ADJUSTED EBITDA
(IN THOUSANDS)
(Unaudited)
         
    Nine Months Ended September 30,
      2026     2025  
         
Net income (loss)   $ 11,640   $ (18,414 )
Depreciation and amortization     30,336     27,984  
Income tax provision     8,991     11,452  
Amortization of basis difference     1,678     1,500  
Interest expense     48,227     90,523  
Stock-based compensation     37,350     23,032  
Loss on extinguishment and modification of debt     1,053     –  
Loss on disposal of property and equipment     892     477  
Fair market value adjustment on debt     654     –  
Severance and executive recruiting(1)     2,253     2,538  
Strategic initiatives and implementation(2)     5,849     3,084  
Transaction costs(3)     2,628     10,363  
Litigation and settlements(4)     4,780     (142 )
Other(5)     444     886  
Adjustments for equity in earnings        
of unconsolidated affiliates(6)     13,464     13,121  
Adjusted EBITDA   $ 170,239   $ 166,404  
         
         
(1)Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
(2)Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives related to the deployment of a new technology system, the development, customization, and integration of a new enterprise resource planning system, and related transformation of our finance organization, including enhancements to our accounting capabilities and internal control processes.
(3)Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
(4)Consists of litigation and settlement costs for matters not related to core operations.
(5)Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
(6)To adjust for Lumexa Imaging’s proportional share of depreciation and amortization, interest expense and losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.

LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(Unaudited)
         
    Three Months Ended September 30,
      2026       2025  
         
Net income (loss)   $ 7,178     $ (3,501 )
         
Stock-based compensation     12,339       8,312  
Loss on disposal of property and equipment     779       623  
Fair market value adjustment on debt     654       –  
Severance and executive recruiting(1)     622       365  
Strategic initiatives and implementation(2)     2,365       1,198  
Transaction costs(3)     (661 )     2,899  
Litigation and settlements(4)     3,578       (14 )
Other(5)     362       728  
Adjustments for equity in earnings        
of unconsolidated affiliates(6)     160       255  
Total adjustments     20,198       14,366  
Tax impact of adjustments(7)     (2,722 )     (1,515 )
Adjusted net income   $ 24,654     $ 9,350  
         
Weighted average shares outstanding        
Basic     95,983,246       69,531,530  
Diluted     96,256,077       69,531,530  
         
Adjusted basic net income per share   $ 0.26     $ 0.13  
Adjusted diluted net income per share   $ 0.26     $ 0.13  
         
         
(1)Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
(2)Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives related to the deployment of a new technology system, the development, customization, and integration of a new enterprise resource planning system, and related transformation of our finance organization, including enhancements to our accounting capabilities and internal control processes.
(3)Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
(4)Consists of litigation and settlement costs for matters not related to core operations.
(5)Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
(6)To adjust for Lumexa Imaging’s proportional share of losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.
(7)Tax effected adjustments using blended federal and state effective income tax rate.

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
SCHEDULE OF ADJUSTED EARNINGS AND EARNINGS PER SHARE
(IN THOUSANDS, EXCEPT PER SHARE DATA)
(Unaudited)
         
    Nine Months Ended September 30,
      2026       2025  
         
Net income (loss)   $ 11,640     $ (18,414 )
         
Stock-based compensation     37,350       23,032  
Loss on disposal of property and equipment     892       477  
Loss on extinguishment and modification of debt     1,053       –  
Fair market value adjustment on debt     654       –  
Severance and executive recruiting(1)     2,253       2,538  
Strategic initiatives and implementation(2)     5,849       3,084  
Transaction costs(3)     2,628       10,363  
Litigation and settlements(4)     4,780       (142 )
Other(5)     444       886  
Adjustments for equity in earnings        
of unconsolidated affiliates(6)     755       309  
Total adjustments     56,658       40,547  
Tax impact of adjustments(7)     (7,183 )     (4,381 )
Adjusted net income   $ 61,115     $ 17,752  
         
Weighted average shares outstanding        
Basic     95,983,242       69,527,181  
Diluted     96,092,916       69,527,181  
         
Adjusted basic net income per share   $ 0.64     $ 0.26  
Adjusted diluted net income per share   $ 0.64     $ 0.26  
         
         
(1)Includes severance and recruiting expenses for executive leadership departures as part of strategic organizational changes.
(2)Includes third-party consulting, implementation, and integration expenses incurred as part of our strategic transformation and optimization initiatives related to the deployment of a new technology system, the development, customization, and integration of a new enterprise resource planning system, and related transformation of our finance organization, including enhancements to our accounting capabilities and internal control processes.                    
(3)Includes costs for third party non-recurring IPO costs, buy-side and sell-side due diligence activities to evaluate and execute potential mergers and acquisitions, integrate acquired businesses and one-time employee retention bonuses related to potential mergers and acquisitions.
(4)Consists of litigation and settlement costs for matters not related to core operations.  
(5)Consists of other costs related to debt financing, certain de novo start-up costs related to outpatient imaging centers and certain exit costs related to closed outpatient imaging centers.
(6)To adjust for Lumexa Imaging’s proportional share of losses/gains on asset disposals, which are included in equity in earnings from unconsolidated affiliates.
(7)Tax effected adjustments using blended federal and state effective income tax rate.

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
DETAILS OF MANAGEMENT FEE AND OTHER REVENUES
(IN THOUSANDS)
(Unaudited)
    Three Months Ended September 30,
      2026     2025
Components of “management fee and other revenues:”        
Fees for managing joint ventured outpatient sites and other third party services   $ 25,889   $ 23,843
Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa     34,969     33,406
Total revenues   $ 60,858   $ 57,249
         
         
         
    Nine Months Ended September 30,
      2026     2025
Components of “management fee and other revenues:”        
Fees for managing joint ventured outpatient sites and other third party services   $ 73,490   $ 64,497
Zero margin pass-throughs of employee, IT and other site level costs paid by Lumexa     103,014     98,672
Total revenues   $ 176,504   $ 163,169

 
LUMEXA IMAGING HOLDINGS, INC. AND SUBSIDIARIES
SEGMENT REVENUES
(IN THOUSANDS)
(Unaudited)
                 
                 
    THREE MONTHS ENDED SEPTEMBER 30, 2026
    OUTPATIENT   PROFESSIONAL   INTERSEGMENT

ELIMINATIONS 		  TOTAL OF

REPORTABLE

SEGMENTS
Revenue                
Net patient service revenue   $ 148,975   $ 66,342   $ (4,202 )   $ 211,115
Management fee and other revenue     52,974     7,884     –       60,858
Total revenues   $ 201,949   $ 74,226   $ (4,202 )   $ 271,973